Parmax Pharma to Raise ₹19.28 Crore, Eyes Change in Control

Parmax Pharma will raise ₹19.28 crore by issuing equity shares and warrants via a preferential issue. The company also plans to increase its authorized capital to ₹10 crore from ₹6 crore.

Reader Takeaway: Capital infusion for growth plus significant shift in company ownership.

What just happened

The Board of Parmax Pharma Ltd has approved a preferential issue of 31,37,586 equity shares and 21,45,145 warrants, each at an issue price of ₹36.50 per security. This corporate action is expected to raise a total of ₹19.28 crore.

Why this matters

This significant capital infusion is intended to provide liquidity and fund business operations or expansion. Crucially, the issue is also designed to facilitate a change in corporate control, as new investors aim to secure majority voting rights.

The backstory

Parmax Pharma is undertaking a restructuring of its capital base. The company's authorized share capital is being increased from ₹6 crore to ₹10 crore to accommodate the issuance of new securities and provide future flexibility.

What changes now

A change in corporate control is anticipated. Incoming acquirers are reportedly seeking majority voting rights through a combination of this preferential allotment, secondary market purchases, and a potential subsequent open offer.

Risks to watch

Existing shareholders will face dilution due to the issuance of new equity shares and warrants. Investors should monitor the strategies and performance under the new management team.

Peer comparison

Information on comparable preferential issues and control changes in the pharmaceutical sector is not available in the filing.

Context metrics (time-bound)

An Extraordinary General Meeting (EGM) is scheduled for July 2, 2026, to obtain shareholder approval for these proposals. Remote e-voting will be open from June 29, 2026, to July 1, 2026.

What to track next

Investors should closely follow the EGM proceedings and the detailed plans of the new controlling group. The future strategic direction and operational performance under new management will be key areas to monitor.